
==== Front
BMC Public Health
BMC Public Health
BMC Public Health
1471-2458
BioMed Central London

19854
10.1186/s12889-024-19854-3
Research
Elevated risk of pre-diabetes and diabetes in people with past history of COVID-19 in northeastern Nigeria
Stephen Roland I. 12
Tyndall Jennifer A. 3
Hsu Hsing-yu 4
Sun Jing 4
Umaru Nura 5
Olumoh Jamiu S. 6
Adegboye Oyelola A. oyelola.adegboye@menzies.edu.au

7
Owobi Olah U. 8
Brown Todd T. 9
1 https://ror.org/042vvex07 grid.411946.f 0000 0004 1783 4052 Department of Internal Medicine, Modibbo Adama University Teaching Hospital, Yola, Adamawa State Nigeria
2 School of Doctoral Studies, Unicaf University, Larnaca, Cyprus
3 https://ror.org/02kv8bx48 grid.442704.1 0000 0004 1764 9500 Department of Natural and Environmental Sciences, American University of Nigeria, Yola, Adamawa State Nigeria
4 grid.21107.35 0000 0001 2171 9311 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
5 Department of Medicine, Federal Teaching Hospital, Gombe, Gombe State Nigeria
6 https://ror.org/02kv8bx48 grid.442704.1 0000 0004 1764 9500 Department of Mathematics and Statistics, American University of Nigeria, Yola, Adamawa State Nigeria
7 https://ror.org/048zcaj52 grid.1043.6 0000 0001 2157 559X Menzies School of Public Health, Charles Darwin University, Casuarina, NT 0810 Australia
8 https://ror.org/02bjqnd50 grid.463571.2 Pro-Health International, Abuja, Nigeria
9 https://ror.org/00za53h95 grid.21107.35 0000 0001 2171 9311 Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University, Baltimore, MD USA
12 9 2024
12 9 2024
2024
24 248523 2 2024
22 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

An increased risk of diabetes mellitus (DM) after COVID-19 has been reported in the United States, Europe, and Asia. The burden of COVID-related DM has yet to be described in Africa, where the overall risk of DM has been increasing rapidly. Our objective was to compare the prevalence of pre-DM and DM in Nigerian individuals with a history of COVID-19 to individuals without known COVID-19 infection.

Methods

We undertook a retrospective cohort study with 256 individuals with a past medical history of COVID-19 with no history of pre-DM or DM and 256 individuals without a history of COVID-19 or pre-DM/DM. Participants were categorized as pre-DM (fasting capillary glucose 100–125 mg/dL) or DM (fasting capillary glucose ≥ 126 mg/dL). We employed univariate and multivariable logistic regression to identify key predictors and adjust for confounders related to hyperglycaemia risk factors. Additionally, we used multinomial logistic regression to analyze the relationship between COVID-19 history and diabetes status, distinguishing between normal, pre-diabetic, and diabetic glucose levels. All models were adjusted for age, gender, hypertension, physical activity, central adiposity, and family history of DM.

Results

Compared to the control group, those with a history of COVID-19 had a similar median age (38 vs. 40 years, p = 0.84), had a higher proportion of men (63% vs. 49%), and had a lower prevalence of central adiposity (waist: hip ratio ≥ 0.90 for males and WHR ≥ 0.85 for females) (48% vs. 56.3%, p = 0.06). Of the 256 with a history of COVID-19, 44 (17%) required in-patient care. The median (interquartile range) time interval between COVID-19 diagnosis and the glycaemic assessment was 19 (IQR: 14, 24) months. Pre-DM prevalence was 27% in the post-COVID-19 group and 4% in the control group, whereas the prevalence of DM was 7% in the post-COVID-19 group and 2% in the control group. After multivariable adjustment, the odds of pre-DM were 8.12 (95% confidence interval (CI): 3.98, 16.58; p < 0.001) higher, and the odds of DM were 3.97 (95% CI: 1.16, 13.63) higher in those with a history of COVID-19 compared to controls. In the adjusted multinomial logistic regression analysis, individuals with a history of COVID-19 exhibited significantly elevated risks for pre-diabetes (RRR = 7.55, 95% CI: 3.76–15.17) and diabetes (RRR = 3.44, 95% CI: 1.01–11.71) compared to those without COVID-19.

Conclusion

Previous COVID-19 was found to be a risk factor for prevalent pre-diabetes and diabetes mellitus in Nigeria. More intensive screening for DM in those with a history of COVID-19 should be considered.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12889-024-19854-3.

Keywords

COVID-19
Diabetes Mellitus
Glycaemic Assessment
Nigeria
Risk factors
NIH/NIAIDK24 AI120834 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcBackground

In addition to pneumonia, COVID-19 is associated with multi-systemic complications, such as coagulopathy, myocarditis, and acute kidney injury [1]. New onset diabetes mellitus (DM) after COVID-19 has also been reported worldwide, predominantly in Asia, Europe, and the US [2, 3] In a systematic review and metanalysis conducted in 2022, it was reported that males who had contracted COVID-19 had a two-fold risk of developing DM when compared to those without a history of COVID-19 [2]. Furthermore, in a related study, the incidence of diabetes post-COVID-19 was estimated to be 15.53 per 1000 person-years [2]. Moreover, the risk of developing type 2 diabetes following COVID-19 was significantly higher, with a relative risk (RR) of 1.70 (95% confidence interval (CI):1.32–2.19), when compared to individuals without a history of COVID-19 [2]. A Korean study also showed that the risk of diabetes in the post-acute phase following COVID-19 was increased when compared to those without COVID-19 (adjusted hazard ratio [HR], 1.30; 95% CI, 1.27 to 1.33) [4], while an Italian-based study found an increased risk (1.6%) of onset DM following COVID-19 [5]. Incident risk is highest in the first six months post-COVID-19 infection [6].

The etiological mechanisms contributing to post-COVID-19 DM have not been fully elucidated. Potential mechanisms include a direct impact on pancreatic beta cells, which may compromise insulin secretion [7, 8]. Other factors, such as steroid therapy in the management of COVID-19 infection, have also been implicated in the pathogenesis of post-COVID-19 diabetes [3, 7–16].

Although the impact of COVID-19 pandemic in Africa has been less pronounced compared to regions, Nigeria, like many other African countries, has faced significant infection rates, resulting in near-term and long-term morbidity and mortality. The data regarding the impact of COVID-19 on DM within the African context is notably limited. The ongoing COVID-19 pandemic may add to the rising burden of DM in Africa, which is already at an epidemic level [10]. Prior to the pandemic, the national pooled prevalence of DM in Nigeria was already a concern at 5.7% [17]. Remarkably, despite an overall decrease to 4.3% in the national pooled prevalence of DM post-COVID-19 [18], the prevalence of pre-diabetes in Nigeria remained high at 13.2% [19]. This study aims to retrospectively examines the comparative prevalence of diabetes and pre-diabetes in individuals with and without a history of COVID-19 in Nigeria, thereby investigating the evolving hypothesis that there is an epidemiological link between COVID-19 and abnormal glucose metabolism.

Methods

Study design and population

The study design comprised a retrospective cohort study of persons with a history of COVID-19 that were identified through [1] the database of the state’s epidemiology unit of the Ministry of Health, [2] the infectious disease and isolation centres in-patient database, and 3) identification of individuals who previously tested positive to COVID-19 conducted by the local disease surveillance notification officers (DSNOs), who are domiciled in the various communities across the two States in northeastern Nigeria (Adamawa and Gombe). The latter group was traced by these DSNOs, who tracked them to their various communities and enlisted them after obtaining informed consent. Conventionally, the DSNOs are trained staff who are responsible for tracking individuals suspected to have been infected in the event of any epidemic outbreak and also obtaining specimens for diagnosis.

The diagnosis of COVID-19 was previously established in this cohort using polymerase chain reaction (PCR) for hospitalized patients and urban dwellers. Rapid antigen test kits were used for non-hospitalized patients and rural dwellers, and were administered by DSNOs.

We excluded those below 18 or over 75 years, pregnant women, and those who self-reported having diabetes or pre-diabetes before the COVID-19 pandemic.

Individuals without a history of COVID-19 and who did not have a self-reported history of diabetes or pre-diabetes served as a control group. However, there was no record to ascertain their prior glycaemic status. We recruited this cohort during a free medical outreach organized in the community solely to recruit the control, during which capillary glucose testing and blood pressure measurements were offered free of charge. Those who self-reported having diabetes or pre-diabetes were excluded from the study. Additional control participants were recruited amongst individuals attending the healthcare facilities either on an outpatient basis to the general outpatient department or as a patient’s relative. Again, those who self-reported being diabetic or pre-diabetic were similarly excluded.

Ethics approval

The ethical approval for this study was granted by the institutional research board of the Modibbo Adama University Teaching Hospital Yola Adamawa State, Nigeria, with approval number MAUTHYOLA/HREC/22/237. All participants gave informed consent to participate in this study.

Data collection

Data were collected from December 2022 to April 2023. Trained DSNOs administered the questionnaire by tracking the COVID-19-positive cohort in their communities. A trained nurse enrolled healthcare workers who met the eligibility criteria in their various healthcare facilities. We collected data on sociodemographic information, behavioural risk factors for DM, personal history of hypertension, and family history of hypertension and DM. Glucose was tested using capillary blood (Accucheck) in participants after 8 h of fasting, and their waist-hip ratio was taken. Blood pressure was measured by adhering to the WHO standardized procedure. Blood pressure was assessed with two separate measurements 30 min apart after resting for at least 5 min in accordance with WHO standardized procedures [20]. Waist circumference was measured using a flexible tape at the level of the midpoint between the ribs and the iliac crest from the front after exhalation [21]. Hip circumference was measured using a flexible tape at the point where the buttocks extend the most when viewed from the side [21].

We targeted a sample size of 256 in each group to detect a difference in diabetes prevalence with an alpha of 0.05 with a power of 80%, assuming a diabetes prevalence in the COVID-19 group of 20.8% [11].

The questionnaire is sectioned into socio-demographics and metabolic risk profiles, including physical activity status, the family history of DM or hypertension, smoking status, and glycaemic status. The Anthropometrics section compromised the waist-hip ratio and blood pressure. Besides the outcomes of the COVID-19 tests, the questionnaire had provisions for the type of care offered, such as in-patient or outpatient care, duration of admission, administration of steroids, and oxygen therapy.

Study outcome

The primary outcome was the prevalence of diabetes and pre-diabetes, defined using criteria established by the American Diabetes Association [2]. Diabetes was defined as a fasting glucose concentration ≥ 7.0 mg/dL and pre-diabetes was defined as a fasting glucose concentration of 5.6–6.9 mmol/l. Capillary blood was used for glycaemic status assessment [22].

Covariates

Hypertension was defined as either a systolic blood pressure ≥ 140 or diastolic ≥ 90 or both or self-reported hypertension on treatment. Central obesity was defined using the adult waist-hip ratio (WHR), male WHR ≥ 0.90, and female WHR ≥ 0.85 [23]. Physical activity was measured using World Health Organization criteria for physical inactivity [24]. Physical inactivity was defined as the failure to meet WHO recommendations on physical activity for health, which are defined as engaging in at least 150 min of moderate-intensity activity per week or 75 min of vigorous-intensity activity per week, through any combination of walking and moderate or vigorous-intensity activities.

Statistical analysis

All statistical analyses were performed using Stata software (version 17.0) and R version 4.0.3. Data were presented as frequencies and percentages for categorical variables. The prevalence of diabetes and pre-diabetes with Clopper-Pearson 95% confidence interval was presented for individuals with and without a history of COVID-19. We used univariate and multivariable logistic regression models for the associated risk factors of hyperglycaemia (diabetes or pre-diabetes) to identify significant predictors and adjust for potential confounders. We assessed the relationship between those with and without a history of COVID-19 and diabetes (normal blood glucose, pre-diabetic and diabetic) using multinomial logistic regression. Normal blood glucose was used as the reference. To control for potential confounding variables, all models were adjusted for age (< 50 vs. ≥50 years), gender (male vs. female), hypertension (yes vs. no), family history of DM (yes vs. no), physical activity (active vs. sedentary), and waist-hip-ratio (normal vs. central obesity).

Results

Figure 1 describes the flowchart for participant recruitment. Initially, 294 potential post-COVID participants were identified; 31 with self-reported diabetes were excluded, and seven declined consent, leaving 256 participants that were included in this study. Of these, 44 were hospitalized, with 16 testing their baseline blood sugar levels at diagnosis; 4 of these developed new-onset diabetes, while the rest were euglycemic. The remaining 240 did not have baseline blood sugar checked. For the control cohort, 300 potential participants were identified, but 44 with self-reported diabetes were excluded.

Fig. 1 Flow chart of participant recruitment and outcomes

Participant characteristics for the two groups are given in Table 1. Among those with a history of COVID-19, a higher percentage were male compared to those without a history of COVID-19 (62.5% vs. 49.4%. p = 0.002). Significant differences in marital status between the two groups were observed. For instance, there were nearly twice as many single individuals in the COVID-19 cohort compared to the control group (26.5% vs. 14.5%). Also, while the majority were married in both cohorts, there were slightly more so in the control group (69.9% vs. 76.2%). Among those with a history of COVID-19, more were likely to have a tertiary education compared to the control group. The occupations varied significantly between the two groups (P < 0.001), with the COVID-19 cohort having more civil servants (27.3% vs. 8.2%) and healthcare workers (16% vs. 0%).

Table 1 Baseline demographic characteristics of study participants

Characteristics	Positive Past medical history of COVID-19 cohort	Control cohort	p-value	
Age, years	39.84	40.74	0.25	
Gender				
Male	160 (62.5%)	126 (49.2%)	0.002	
Female	96 (37.5%)	130 (50.8%)		
Marital Status				
Divorced	3 (1.2%)	9 (3.5%)	0.001	
Married	179 (69.9%)	195 (76.2%)		
Single	68 (26.5%)	37 (14.5%)		
Widowed	6 (2.3%)	15 (5.9%)		
Education				
No formal education	30 (11.7%)	149 (58.2%)	< 0.001	
Primary school	29 (11.3%)	19 (7.4%)		
Secondary	96 (37.5%)	54 (21.1%)		
Tertiary	101 (39.5%)	34 (13.3%)		
Occupation				
Artisan	3 (1.2%)	14 (5.5%)	< 0.001	
Civil Servant	70 (27.3%)	21 (8.2%)		
Farmer	61 (23.8%)	93 (36%)		
Full time housewife	21 (8.2%)	36 (14.1%)		
Healthcare Worker	41 (16%)	0 (0%)		
None	1 (0.4%)	14 (5.5%)		
Student	30 (11.7%)	5 (2%)		
Trader/Business	25 (9.8%)	57 (22.3%)		
Others	3 (1.2%)	16 (6.3%)		
Blood pressure		0.059	
Hypertensive	68 (26.6%)	50 (19.5%)		
Normotensive	188 (73.4%)	206 (80.5%)		
Fam Hx of NCD			< 0.001	
Diabetes	5 (2.0%)	7 (3%)		
Diabetes/ Hypertension	15 (5.9%)	2 (1%)		
Hypertension	103 (40.2%)	27 (11%)		
Uknown	27 (10.5%)	18 (7%)		
None	106 (41.4%)	202 (79%)		
Physical Activity			0.658	
Active	135 (53%)	130 (50.8%)		
Sedentary	121 (47%)	126 (49.2%)		
Admission (weeks)				
Hospitalized	44 (17%)			
Not-Hospitalized	212 (83%)			
New onset in-hospital DM				
No	252 (98%)			
Yes	4 (2%)			
Steroid use				
No	240 (94%)			
Yes	16 (6%)			
Waist-Hip-ratio			0.063	
central obesity	123 (48%)	144 (56.3%)		
normal build	133 (52%)	112 (43.8%)		
Glycaemic status			0.268	
Diabetic	12 (4.7%)	4 (1.6%)		
Prediabetes	68 (26.6%)	11 (4.3%)		
Euglycemic	176 (68.8)	241 (94.1%)		

We observed significant differences in the prevalence of diabetes in the COVID-19, and the control groups were 4.6% (0.046, 95% CI: 0.024–0.08) and 1.6% (0.016, 95% CI: 0.004–0.039), respectively (Fig. 2). The prevalence of pre-diabetes in the COVID-19 and the control cohorts were 26.6% (0.266, 95% CI: 0.213–0.324) and 4.3% (0.043, 95% CI: 0.022–0.075), respectively. Results from univariate and multivariable logistic regression models for the associated risk factors of hyperglycaemia (diabetes or pre-diabetes) (Supplementary Table S1A-B) show a substantially increased likelihood of hyperglycaemia (fasting glucose 100 mg/dL) among individuals with a past COVID-19 infection compared to those without such a history, in both univariate (OR = 7.45, 95% CI: 4.13–13.41, p < 0.0001) and multivariable models (aOR = 7.15, 95% CI: 3.79–13.50, p < 0.0001). Furthermore, hypertension (aOR = 2.07, 95% CI: 1.12–3.82, p = 0.021) and physical inactivity (aOR = 3.17, 95% CI: 1.81–5.57, p < 0.0001) were significant risk factors for diabetes after excluding those who were exposed to steroid. Other risk factors such as age, gender, family history of diabetes, and central obesity were not associated with prevalent diabetes in this cohort.

Fig. 2 Prevalence of hyperglyceamia between those with a history of COVID-19 COVID (+) and those without COVID (-)

In the multivariable multinomial logistic regression models (Table 2), the risk of pre-diabetes (vs. normoglycemia) was about eight-fold higher in those with a history of COVID-19 (RRR = 7.55, 95% CI: 3.76–15.17, p < 0.0001) compared to those without a history of COVID-19. Similarly, the risk of diabetes (vs. normoglycemia) was three-fold higher in those with a history of COVID-19 3.97 (RRR = 3.44, 95% CI: 1.01–11.71, p = 0.028) compared to those without a history of COVID-19. Age and gender were not a significant predictor of having pre-diabetes or diabetes. Hypertension was also not significantly associated with having pre-diabetes but was associated with having diabetes (RRR = 4.63, 95% CI: 1.45–14.84, p = 0.01). Individuals with low physical activity had higher odds of having pre-diabetes (RRR = 2.87, 95% CI: 1.57–5.24, p = 0.001) and diabetes (RRR = 4.86, 95% CI: 1.43–16.56, p = 0.011) compared to active individuals. Results from sensitivity analyses excluding the 16 participants who received steroids during admission for COVID-19 were similar (Supplementary Table S2).

Table 2 Multinomial logistic regression of the risk of diabetes and pre-diabetes in individuals with and without a past history of COVID-19 (inclusive of those treated with steroids)

Variable	Pre-diabetic vs. Normal	Diabetic vs. Normal	
RRR (95% CI)	p-value	RRR (95% CI)	p-value	
COVID-19					
 No	Ref.		Ref.		
 Yes	7.55 (3.76, 15.17)	< 0.001	3.44 (1.01, 11.71)	0.048	
Age					
 < 50	Ref.		Ref.		
 >=50	0.68 (0.34, 1.38)	0.291	2.04 (0.66, 6.31)	0.216	
Gender					
 Male	Ref.		Ref.		
 Female	0.77 (0.43,1.38)	0.377	0.54 (0.15, 1.86)	0.326	
Hypertension					
 No	Ref.		Ref.		
 Yes	1.45 (0.76, 2.78)	0.261	4.23 (1.35, 13.28)	0.014	
Family history of DM					
 No	Ref.		Ref.		
 Yes	1.47 (0.63, 3.40)	0.372	0.64 (0.07, 5.54)	0.686	
Physical activity					
 Active	Ref.		Ref.		
 Sedentary	2.33 (1.31, 4.13)	0.004	4.18 (1.24, 14.04)	0.021	
Waist-hip-ratio					
 Normal	Ref.		Ref.		
 Central obesity	1.72 (0.93, 3.18)	0.082	1.04 (0.33, 3.25)	0.952	

Discussion

To the best of our knowledge, this is the first study to examine the prevalence of DM and pre-diabetes in those with and without a history of COVID-19 in Africa, an area that has one of the fastest-growing populations with DM. We showed that the prevalence of DM and pre-DM in persons with a known history of COVID-19 was higher than in those without a history of COVID-19. Our findings suggest that COVID-19 may be a risk factor for pre-diabetes and diabetes in this population.

In our study based in Northeastern Nigeria, we found the prevalence of diabetes mellitus to be higher among those with a history of COVID-19 compared to participants without a known history of COVID-19. The observed prevalence in those with a history of COVID-19 was higher than the subregional (northeastern Nigeria) prevalence of DM of 3.8% (95% CI: 2.7–4.7) [12]. Previous studies have also shown a higher risk of diabetes-related to COVID-19 in other areas of the world. In a recent Canadian study, the risk of diabetes in individuals with a history of COVID-19 was 0.5%, as opposed to 0.4% in those without COVID-19 [25]. The study further revealed that COVID-19 accounted for 3.41% of DM in the studied population. In their systematic review and metanalysis, Jiajun et al [26] revealed that a history of COVID-19 increased the risk of DM and hyperglycaemia by 1.7-fold compared to those without a history of COVID-19. In the Indian experience, new-onset diabetes among individuals with a history of COVID-19 was observed in 16.7% three months post COVID-19 [13]. Though this study implicated other factors such as age, adiposity, and family history of diabetes in post COVID-19 DM, the observed prevalence is higher than the national prevalence of DM in India of 9.3% [27] At variance with our study, a Chinese-based study reported a 10.3% prevalence of diabetes among COVID-19 patients, which showed almost no difference in the prevalence of 10.9% in the general Chinese population [14]. Additionally, Rathmann et al. [28] reported a higher incidence of diabetes in those with a history of COVID-19 than in those with other types of common acute viral upper respiratory infections (15.8 vs. 12.3 per 1000 person-years) in Germany [28].

The high prevalence of mild COVID-19 could account for the relatively lower prevalence of diabetes in our study. Studies have shown that the incidence of post COVID-19 DM increases with the severity of COVID-19 [16]. According to a systematic review, the global prevalence of pre-diabetes is 5.8% [29], while the pooled national prevalence of pre-diabetes in Nigeria was estimated at 13.2% [19]. Given that pre-diabetes is a major risk factor for the development of DM, identification of this population may have important public health consequences.

It is thought that COVID-19 triggers the pathogenic process of DM by first initiating insulin resistance, then pre-diabetes, and finally frank diabetes [7]. In addition, other pathophysiologic mechanisms are heightened inflammatory state, disruption of the angiotensin-converting enzyme ACEI/ACE2 balance, and subsequent dysfunction of the renin-angiotensin aldosterone-system RAAS [30]. Of note is the direct pancreatic beta cell destruction by the SARS-COV2 [30]. The extent to which this population is at risk of the development of diabetes mellitus deserves further study.

The relationship between COVID-19 and diabetes mellitus may be bidirectional [7, 14, 31]. Hence, it is possible that the cases of previously undiagnosed diabetes are being recognized during a clinical encounter related to COVID-19. This possibility was suggested by a US-based study which showed that persons with COVID-19 were 40% more likely to be diagnosed with diabetes mellitus compared to those without COVID-19 [32]. In our study, although participants with a history of COVID-19 reported no pre-existing diabetes before the study assessment, it is possible that hyperglycaemia was present at the time of COVID-19 diagnosis but was not clinically apparent.

For severe COVID-19, glucocorticoids are indicated for lung disease, which may, in turn, increase the risk of diabetes mellitus [13, 33, 34]. For example, in an Indian study, of the 31 individuals who had been treated with steroids while on admission for COVID-19, eleven (35.5%) went on to develop new-onset diabetes three months later [13]. Our study results are unlikely to be related to glucocorticoid use. In a sensitivity analysis, excluding those who reported glucocorticoid use as a treatment for COVID-19, there is a higher odds of prevalent diabetes and pre-diabetes among those with COVID-19 compared to the control group persisted [33].

Inpatient care, which connotes severe COVID-19 disease, has been associated with a higher risk of post-COVID-19 DM and, consequently, a higher burden of DM [35]. This study had only a 17% admission rate, which may possibly explain the relatively lower prevalence of post-COVID-19 DM observed. This finding of the high prevalence of pre-DM in individuals with history of COVID-19 speaks to the public health policymakers to enact a policy framework that would lead to regular monitoring of the glycaemic status of this cohort. In addition, the policy should provide them with health education on the need for lifestyle modification and behavioural changes to reduce the risk for DM in the future, thereby decreasing the burden of DM.

We acknowledge the following limitations in our study. First, most of our participants did not have a glucose determination at the time of or before their COVID-19 diagnosis. We, therefore, are unable to fully exclude persons with pre-existing diabetes. Second, we used capillary glucose for diabetes determination, which, while suitable for epidemiologic studies, may be slightly different than plasma glucose. An additional assessment with HbA1c could also have been useful to better categorize glycaemic status. Similarly, we did not carry out COVID-19. antibody testing for the control group. Being predominantly retrospective in design, it is not shielded from the inherent recall bias of this design. Lastly, the two cohorts differed on important characteristics which we attempted to balance with multivariable adjustment.

Recruiting participants through healthcare facilities could have introduced some selection bias. This is because some individuals who might have had asymptomatic or mild COVID-19 and never presented to the healthcare facilities for testing would not have been identified as having COVID-19. In addition, bias could have been introduced by virtue of socioeconomic status. People of low socioeconomic status are less likely to seek healthcare than those with higher socioeconomic status. In this regard, some participants of low socioeconomic status with characteristic symptoms of COVID-19 were unable to receive diagnostic testing due to their financial constraints. Furthermore, causal inference is limited in a cross-section study and longitudinal studies are needed to establish temporality and provide added evidence of a causal relationship between COVID-19 and DM. Finally, we did not screen for other viruses, such as hepatitis C viral infection, which is endemic and has been associated with DM.

Conclusion

In conclusion, our study suggests that a history of COVID-19 may be a risk factor for diabetes and pre-diabetes in Nigeria. If confirmed in longitudinal studies, more aggressive screening for DM may be warranted among those who have a history of COVID-19. Further studies are also needed to determine the risk of transition to DM in those with a history of COVID-19 with pre-diabetes and what interventions can be implemented to decrease this risk.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Supplementary Material 2

Acknowledgements

TTB is supported in part by K24 AI120834.

Author contributions

RIS and JT conceived the project and drafted the manuscript. VH, JS, JO, and OA conducted data analysis JO, OA, RIS and TTB supervised the methodological approach and interpretation of results. RIS, JT, VH, JS, NU, JO, OA, OUO and TTB contributed to study design, introduction, discussion and critical interpretation of results. JT and RIS led ethics application and project management. All authors critically revised the manuscript for intellectual content. All authors read and approved the final manuscript.

Funding

None.

Data availability

The dataset supporting the conclusions of this article is included within the article (and its additional files).

Declarations

Ethics approval and consent to participate

The ethical approval for this study was granted by the institutional research board of the Modibbo Adama University Teaching Hospital Yola Adamawa State, Nigeria, with approval number MAUTHYOLA/HREC/22/237. Informed consent was obtained from all participants in this study.

Consent for publication

Informed consent was obtained from all participants in this study. Written informed consents for publication were obtained from the participants.

Competing interests

TTB has served as a consultant to Gilead Sciences, Merck, ViiV Healthcare, and Janssen.

Abbreviations

aOR Adjusted odds ratio

ACEI/ACE2 Angiotensin-converting enzyme

DM Diabetes mellitus

COVID-19 Coronavirus disease 2019

OR Odds ratio

RR Relative risk

RRR Relative risk ratio

DSNO Disease surveillance notification officer

PCR Polymerase chain reaction

RAAS Renin-angiotensin aldosterone-system

SARS-COV2 Severe acute syndrome coronavirus 2

WHR Waist-hip ratio

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. White-Dzuro G, Gibson LE, Zazzeron L, White-Dzuro C, Sullivan Z, Diiorio DA, et al. Multisystem effects of COVID-19: a concise review for practitioners. Postgraduate Medicine. Volume 133. Bellwether Publishing, Ltd.; 2021. pp. 20–7.
2. Zhang T Mei Q Zhang Z Walline JH Liu Y Zhu H Risk for newly diagnosed diabetes after COVID-19: a systematic review and meta-analysis BMC Med 2022 20 1 444 10.1186/s12916-022-02656-y 36380329
Zhang T, Mei Q, Zhang Z, Walline JH, Liu Y, Zhu H, et al. Risk for newly diagnosed diabetes after COVID-19: a systematic review and meta-analysis. BMC Med. 2022;20(1):444.36380329 10.1186/s12916-022-02656-y
3. Shrestha DB Budhathoki P Raut S Adhikari S Ghimire P Thapaliya S New-onset diabetes in COVID-19 and clinical outcomes: a systematic review and meta-analysis World J Virol 2021 10 5 275 87 10.5501/wjv.v10.i5.275 34631477
Shrestha DB, Budhathoki P, Raut S, Adhikari S, Ghimire P, Thapaliya S, et al. New-onset diabetes in COVID-19 and clinical outcomes: a systematic review and meta-analysis. World J Virol. 2021;10(5):275–87.34631477 10.5501/wjv.v10.i5.275
4. Choi JH Kim KM Song K Seo GH Risk for newly diagnosed type 2 diabetes Mellitus after COVID-19 among Korean adults: a Nationwide Matched Cohort Study Endocrinol Metabolism 2023 38 2 245 52 10.3803/EnM.2023.1662
Choi JH, Kim KM, Song K, Seo GH. Risk for newly diagnosed type 2 diabetes Mellitus after COVID-19 among Korean adults: a Nationwide Matched Cohort Study. Endocrinol Metabolism. 2023;38(2):245–52.10.3803/EnM.2023.1662
5. Bellia C, Andreadi A, D’Ippolito I, Scola L, Barraco S, Meloni M, et al. Prevalence and risk of new-onset diabetes mellitus after COVID-19: a systematic review and meta-analysis. Frontiers in Endocrinology. Volume 14. Frontiers Media SA; 2023.
6. Chourasia P, Goyal L, Kansal D, Roy S, Singh R, Mahata I, et al. Risk of New-Onset Diabetes Mellitus as a Post-COVID-19 Condition and possible mechanisms: a scoping review. Volume 12. Journal of Clinical Medicine. MDPI; 2023.
7. Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nature Reviews Endocrinology. Volume 17. Nature Research; 2021. pp. 11–30.
8. Dallavalasa S, Tulimilli SRV, Prakash J, Ramachandra R, Madhunapantula SRV, Veeranna RP. COVID-19: diabetes perspective—pathophysiology and management. Volume 12. Pathogens. MDPI; 2023.
9. Zhang T, Mei Q, Zhang Z, Walline JH, Liu Y, Zhu H et al. Risk for newly diagnosed diabetes after COVID-19: a systematic review and meta-analysis. BMC Med. 2022;20(1).
10. Dessie G, Mulugeta H, Amare D, Negesse A, Wagnew F, Getaneh T, et al. A systematic analysis on prevalence and sub-regional distribution of undiagnosed diabetes mellitus among adults in African countries. Journal of Diabetes and Metabolic Disorders. Volume 19. Springer Science and Business Media Deutschland GmbH; 2020. pp. 1931–41.
11. Li H Tian S Chen T Cui Z Shi N Zhong X Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19 Diabetes Obes Metab 2020 22 10 1897 906 10.1111/dom.14099 32469464
Li H, Tian S, Chen T, Cui Z, Shi N, Zhong X, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab. 2020;22(10):1897–906.32469464 10.1111/dom.14099
12. Uloko Baba M, Musa Mansur A, Ramalan Ibrahim D, Gezawa Fabian H, Puepet Ayekame T, Uloko Musa M, Borodo Kabiru B, Sada AE. Prevalence and Risk Factors for Diabetes Mellitus in Nigeria: A Systematic Review and Meta-Analysis. Diabetes Therapy [Internet]. 9.
13. Keerthi B Sushmita G Khan E Thomas V Cheryala V Shah C New onset diabetes mellitus in post-COVID-19 patients J Family Med Prim Care 2022 11 10 5961 10.4103/jfmpc.jfmpc_316_22 36618178
Keerthi B, Sushmita G, Khan E, Thomas V, Cheryala V, Shah C, et al. New onset diabetes mellitus in post-COVID-19 patients. J Family Med Prim Care. 2022;11(10):5961.36618178 10.4103/jfmpc.jfmpc_316_22
14. Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. Journal of Endocrinological Investigation. Volume 43. Springer; 2020. pp. 867–9.
15. Sathish T, Kapoor N, Cao Y, Tapp RJ, Zimmet P. Proportion of newly diagnosed diabetes in COVID-19 patients: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism. Volume 23. Blackwell Publishing Ltd; 2021. pp. 870–4.
16. Singh AK Gupta R Ghosh A Misra A Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations Diabetes Metabolic Syndrome: Clin Res Reviews 2020 14 4 303 10 10.1016/j.dsx.2020.04.004
Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metabolic Syndrome: Clin Res Reviews. 2020;14(4):303–10.10.1016/j.dsx.2020.04.004
17. Adeloye D, Ige JO, Aderemi AV, Adeleye N, Amoo EO, Auta A et al. Estimating the prevalence, hospitalisation and mortality from type 2 diabetes mellitus in Nigeria: a systematic review and meta-analysis. BMJ Open. 2017;7(5).
18. World Health Organization. Stakeholders call for increased access to diabetes education. 14 November 2022. Abuja, Nigeria. Assessed 12 August 2023. https://www.afro.who.int/countries/nigeria/news/stakeholders-call-increased-access-diabetes-education
19. Bashir MA, Yahaya AI, Muhammad M, Yusuf AH, Mukhtar IG. Prediabetes Burden in Nigeria: a systematic review and Meta-analysis. Frontiers in Public Health. Volume 9. Frontiers Media S.A.; 2021.
20. John O Campbell NRC Brady TM Farrell M Varghese C Velazquez Berumen A The 2020 ‘WHO Technical specifications for automated non-invasive blood pressure Measuring Devices with Cuff’ Hypertension 2021 77 3 806 12 10.1161/HYPERTENSIONAHA.120.16625 33517681
John O, Campbell NRC, Brady TM, Farrell M, Varghese C, Velazquez Berumen A, et al. The 2020 ‘WHO Technical specifications for automated non-invasive blood pressure Measuring Devices with Cuff’. Hypertension. 2021;77(3):806–12.33517681 10.1161/HYPERTENSIONAHA.120.16625
21. Okeahialam B. Article in West African journal of medicine [Internet]. 2011. https://www.researchgate.net/publication/232745752
22. Kruijshoop M Feskens EJM Blaak EE De Bruin TWA Validation of capillary glucose measurements to detect glucose intolerance or type 2 diabetes mellitus in the general population Clin Chim Acta 2004 341 1–2 33 40 10.1016/j.cccn.2003.10.033 14967156
Kruijshoop M, Feskens EJM, Blaak EE, De Bruin TWA. Validation of capillary glucose measurements to detect glucose intolerance or type 2 diabetes mellitus in the general population. Clin Chim Acta. 2004;341(1–2):33–40.14967156 10.1016/j.cccn.2003.10.033
23. Avan A, Digaleh H, Di Napoli M, Stranges S, Behrouz R, Shojaeianbabaei G et al. Socioeconomic status and stroke incidence, prevalence, mortality, and worldwide burden: an ecological analysis from the global burden of Disease Study 2017. BMC Med. 2019;17(1).
24. Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. British Journal of Sports Medicine. Volume 54. BMJ Publishing Group; 2020. pp. 1451–62.
25. Naveed Z Velásquez García HA Wong S Wilton J McKee G Mahmood B Association of COVID-19 infection with Incident Diabetes JAMA Netw Open 2023 6 4 e238866 10.1001/jamanetworkopen.2023.8866 37071420
Naveed Z, Velásquez García HA, Wong S, Wilton J, McKee G, Mahmood B, et al. Association of COVID-19 infection with Incident Diabetes. JAMA Netw Open. 2023;6(4):e238866.37071420 10.1001/jamanetworkopen.2023.8866
26. Li J, Li Y, Wang Z, Liu N, He L, Zhang H. Increased risk of new-onset diabetes in patients with COVID-19: a systematic review and meta-analysis. Frontiers in Public Health. Volume 11. Frontiers Media S.A.; 2023.
27. Mathur P, Leburu S, Kulothungan V, Prevalence. Awareness, Treatment and Control of Diabetes in India from the Countrywide National NCD Monitoring Survey. Front Public Health. 2022;10.
28. Rathmann W, Kuss O, Kostev K. Incidence of newly diagnosed diabetes after Covid-19. 10.1007/s00125-022-05670-0
29. Rooney MR Fang M Ogurtsova K Ozkan B Echouffo-Tcheugui JB Boyko EJ Global prevalence of Prediabetes Diabetes Care 2023 46 7 1388 94 10.2337/dc22-2376 37196350
Rooney MR, Fang M, Ogurtsova K, Ozkan B, Echouffo-Tcheugui JB, Boyko EJ, et al. Global prevalence of Prediabetes. Diabetes Care. 2023;46(7):1388–94.37196350 10.2337/dc22-2376
30. Rizvi AA, Kathuria A, Al Mahmeed W, Al-Rasadi K, Al-Alawi K, Banach M, et al. Post-COVID syndrome, inflammation, and diabetes. Journal of Diabetes and its Complications. Volume 36. Elsevier Inc.; 2022.
31. Khunti K Prato S Del, Mathieu C Kahn SE Gabbay RA Buse JB Covid-19, hyperglycemia, and new-onset diabetes Diabetes Care 2021 44 12 2645 55 10.2337/dc21-1318 34625431
Khunti K, Prato S, Del, Mathieu C, Kahn SE, Gabbay RA, Buse JB. Covid-19, hyperglycemia, and new-onset diabetes. Diabetes Care. 2021;44(12):2645–55.34625431 10.2337/dc21-1318
32. Sharma A Misra-Hebert AD Mariam A Milinovich A Onuzuruike A Koomson W Impacts of COVID-19 on Glycemia and Risk of Diabetic Ketoacidosis Diabetes 2023 72 5 627 37 10.2337/db22-0264 36107493
Sharma A, Misra-Hebert AD, Mariam A, Milinovich A, Onuzuruike A, Koomson W, et al. Impacts of COVID-19 on Glycemia and Risk of Diabetic Ketoacidosis. Diabetes. 2023;72(5):627–37.36107493 10.2337/db22-0264
33. Wrona M, Skrypnik D. New-Onset Diabetes Mellitus, Hypertension, Dyslipidaemia as Sequelae of COVID-19 infection—systematic review. Volume 19. International Journal of Environmental Research and Public Health. MDPI; 2022.
34. Rana MA Siddiqui H Raza M Tehreem S Mahmood K Javed MFU Incidence of steroid-induced diabetes in COVID-19 patients Pakistan J Med Health Sci 2021 15 10 2595 6 10.53350/pjmhs2115102595
Rana MA, Siddiqui H, Raza M, Tehreem S, Mahmood K, Javed MFU. Incidence of steroid-induced diabetes in COVID-19 patients. Pakistan J Med Health Sci. 2021;15(10):2595–6.10.53350/pjmhs2115102595
35. Fernóandez-De-las-Penas C Guijarro C Torres-Macho J Velasco-Arribas M Plaza-Canteli S Hernóandez-Barrera V Diabetes and the risk of long-term Post-COVID symptoms Diabetes 2021 70 12 2917 21 10.2337/db21-0329 34580087
Fernóandez-De-las-Penas C, Guijarro C, Torres-Macho J, Velasco-Arribas M, Plaza-Canteli S, Hernóandez-Barrera V, et al. Diabetes and the risk of long-term Post-COVID symptoms. Diabetes. 2021;70(12):2917–21.34580087 10.2337/db21-0329
